A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes

Sarah Joseph1, Killian Quinn2, Aldona Greenwood3, Alethea V. Cope2, Paul F. McKay2, Peter J. Hayes4, Jakub T. Kopycinski4, Jill Gilmour4, Aleisha N. Miller5, Christof Geldmacher6,7, Yuka Nadai6,7, Mohamed I. M. Ahmed6,7, David C. Montefiori8, Len Dally9, George Bouliotis5, David J. M. Lewis3,10, Roger Tatoud2, Ralf Wagner11, Mariano Esteban12, Robin J. Shattock2, Sheena McCormack* and Jonathan Weber2

1MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK, 2Department of Medicine, Imperial College London, London, UK, 3Clinical Research Centre, University of Surrey, Guildford, UK, 4IAVI Human Immunology Laboratory, Imperial College London, London, UK, 5ICTU, Department of Public Health, Imperial College London, London, UK, 6Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany, 7German Centre for Infection Research (DZIF), Munich, Germany, 8Duke University Medical Centre, Durham, NC, USA, 9The EMMES Corporation, Rockville, MD, USA, 10Clinical Research Facility, Imperial College Healthcare NHS Trust, London, UK, 11University of Regensburg and University Hospital Regensburg, Regensburg, Germany, 12National Center for Biotechnology, CSIC, Madrid, Spain

There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4⁺ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant—aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included ≥ grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥ grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders, p = 0.04). T-cell ELISpot responses were CD4⁺ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most
immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in >80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.

**Keywords:** HIV vaccine, phase I trial, DNA, MVA, envelope protein

**INTRODUCTION**

In an era of antiretroviral medication for the treatment and prevention of HIV, concerns around access, toxicity, and escalating cost suggest that a vaccine for HIV is still likely to be the most effective and sustainable way of reducing new infections (1, 2). Of the five HIV efficacy vaccine trials to date, there has only been one to demonstrate significant, if modest efficacy; the RV144 “Thai” trial (3–8). This study with 16,402 subjects randomized to four immunizations with ALVAC given twice and then twice more with AIDSVAX B/E adjuvanted with ALUM, reported 31.2% protection (95% CI 1–51) against acquisition, without impacting HIV viral load or CD4+ T cell count (8). Subsequent immunological analyses reported an inverse correlation between the levels of circulating polyclonal non-neutralizing antibodies and risk of infection, which has been associated with Fc receptor-mediated antibody effector functions (9–15). The results stimulated interest in prime-boost pox and protein combination vaccine approaches and the role of non-neutralizing antibodies.

Heterologous prime boost regimens employing DNA, viral vectors, and/or recombinant proteins have generated robust cellular and humoral responses maximizing breadth and potency while limiting the attenuating effects of vector specific immunity (16–20). DNA vaccines have been shown to prime cellular and humoral immune responses, upon boosting with recombinant vectors (21). The EuroVacc trials demonstrated that DNA prime, NYVAC boost increased the frequency, magnitude, and breadth of HIV-specific T-cell ELISpot responses (22, 23) and that three DNA priming immunizations were more immunogenic than two (24). A recent clinical trial comparing different prime boost regimens showed no benefit of DNA priming for Env-specific antibody responses but evidence of an improvement in T-cell responses, although overall immunogenicity was lower than seen previously in response to the same DNA and MVA vaccines (25).

In this study, the UK HIV Vaccine Consortium built upon these prior data showing enhanced immunogenicity of DNA prime, pox vector boost, and the protection seen in RV144 by protein boosting, to produce homologous DNA, MVA, and gp140 immunogens. We have made DNA plasmids and an MVA expressing matched HIV-1 subtype C (CN54)-derived inserts, and adjuvanted trimeric glycoprotein with a view for use in Sub-Saharan Africa. We believe this strategy is ideally suited to inducing Env-dominant CD4+ T-cell responses, favoring the development of high titer Env-specific antibody responses. The same trimeric recombinant CN54gp140 protein has already been administered to 469 individuals in a variety of trial settings (with and without DNA priming, or adjuvant and via different routes), showing excellent safety and induction of vaccine specific antibodies (26–28). When given systemically with glucopyranosyl lipid adjuvant—aqueous formulation (GLA-AF) after priming with heterologous DNA and MVA, high titer systemic binding antibodies were seen to the protein (28).

Prompted by the results of the RV144 trial, but with long-term feasibility in mind, we have explicitly assessed the impact of combining pox (MVA-C) and GLA-AF adjuvanted CN54gp140 protein after priming with DNA. We compared the safety and immunogenicity of two regimens using identical vaccines; given sequentially in one regimen (standard) and with the pox and protein combined in the other (accelerated). We shortened the regimens relative to our previous studies and RV144 by reducing the intervals between vaccinations, with 4 weeks between each of three DNA immunizations, 8 weeks between prime and first boost, and 4 weeks between subsequent boosts. We administered vaccinations intramuscularly (IM) for logistical ease and with a view to eventual roll out in resource limited settings.

The DNA and MVA-C were produced by UK HVC and based closely on those used previously (EV02 Eudract 2004-001802-28 and EV03 Eudract 2006-006141-13), with matched CN54/ZM96 subtype C-derived gag pol nef and env inserts. We anticipated Env-dominated CD4+ T-cell responses and modest Env-specific antibody responses after DNA and MVA, with the development of high titer binding and neutralizing antibody responses after boosting with adjuvanted CN54gp140 protein (29–31). Based on our previous studies, we expected that the immunogens would prove more potent B-cell immunogens than the ALVAC/ AIDSVAX/ALUM used in RV144 and that the combined MVA/ CN54gp140/GLA might augment immunogenicity, offering the potential for a short regimen.

**MATERIALS AND METHODS**

**Study Design and Conduct**

This was a Phase I randomized open-label trial conducted at two UK centers: Imperial College London and Surrey Clinical Research Centre. Participants were recruited through advertising,
social media, and a dedicated website. The study documents were reviewed and approved by the NRES London—West London and GTAC Ethics Committee (13/LO/0115), and the UK Medicines and Healthcare products Regulatory Agency, and all participants gave fully informed written consent according to the Declaration of Helsinki before any study procedures were conducted. The trial was registered with the European Union Drug Regulating Authorities for Clinical Trials (EUDRACT TC 2012-003277-26) and Clinical Trials.gov (NCT01922284) and with the UK Clinical Trials Research Network (UKRN-14173). Laboratory personnel were blind to the allocation. Participants were block randomized centrally using a computer generated algorithm with a back-up manual procedure, and the randomization list was stratified by center and gender.

The primary objective was to compare the safety and immunogenicity of two vaccination regimens, one of which was shortened by 8 weeks (Figure 1) in healthy HIV-uninfected male and female volunteers aged 18–45 years at low risk of HIV infection. The primary outcomes were (i) a severe (grade 3) or worse local or systemic clinical or laboratory adverse event or an event that led to a clinical decision to discontinue vaccinations and (ii) the magnitude of the CN54gp140-specific IgG antibody response in serum 4 weeks after the final immunization. Secondary outcomes of interest included IFNγ T-cell ELISPOT, intracellular cytokine, neutralizing antibody, CN54gp140-specific serum IgA, mucosal IgG, and IgA antibody responses.

Safety Evaluations

Local and systemic events recognized to be associated with licensed vaccines were solicited systematically at clinical centers prior to, 10 min and 1 h after each vaccination, and then 7 days later, and by diary card. Clinical and laboratory events were collected via an open question at each visit and through routine hematology and chemical pathology performed at screening, 1 week after each vaccination and at week 40 in both groups.
**Immunological Specimens**

Blood was taken for immunological assessments at weeks 0, 4, 8, 16, 20, and 24 and 40 for all participants and at weeks 28 and 32 for those in the standard group. Mucosal samples were collected at weeks 0 and 24 for the accelerated and at weeks 0 and 32 for the standard group. Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient separation, frozen in a mixture of fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and DMSO (9:1 ratio) using a Kryo 560-16 rate controlled freezer (Planer, Sunbury-On-Thames, UK). PBMCs were shipped and stored in vapor phase liquid nitrogen as previously (32). Genital tract secretions were from women collected using the Instead Softcup™ (Evoferm Inc.) and urethral swabs (Hunt Biologics, UK) from male volunteers and rectal Floq™ swabs were taken when possible from males and females, primarily to assess the feasibility of the sampling method. Vaginal samples were collected, processed, and analyzed as described previously (33). Processing involved addition of 300 µl of extraction buffer [250 mM NaCl, 1× protease inhibitor cocktail set 1 (Calbiochem) in phosphate buffered saline (PBS)] to the swabs, vortexing for 1 min and placing on ice to 15 min. Rectal and urethral swabs were then placed in the top chamber of a spin X tube, centrifuged at max speed (10,000 g) for 2 min and the eluates either analyzed immediately or aliquoted and frozen at −80°C until analysis.

**Vaccines and Schedule**

The recombinant clade C HIV-1 envelope gp140 protein (CN54gp140) is a naturally cleavage resistant envelope clone of 97CN54 (34). The protein was manufactured to GMP specifications (33) (Polymun Scientific Austria) generating a product which was >80% trimeric protein with a projected mass of 420 kD and a defined glycan (35). A total of 100 µg CN54gp140 was mixed with 5 µg GLA-AD (IDRI, Seattle, WA, USA) and administered in a volume of 0.4 ml as below. There were two DNA plasmids; one encoded (CN54) env and the other a (ZM96) gag-pol-nef fusion protein. Both open-reading frames were RNA and codon optimized (GeneArt AG, Regensburg, Germany). Both plasmids utilized a chimeric CMV enhancer/promoter with a human T-cell leukemia type 1 regulatory element to drive expression (36). The MVA-C (Mariano Esteban CSIC, Spain) expressed the CN54gp120 Env and Gag-Pol-Nef polyprotein from two back-to-back synthetic early/late transcriptional promoters (37, 38). All vaccinations were given IM into the deltoid muscles of the upper arms. 4 mg of each DNA plasmid was given to all participants at weeks 0, 4, and 8 in a volume of 1.0 ml (8.0 mg in total) with the same plasmid given into the same arm on each occasion (CN54 plasmid into right arm and ZM96 into left arm). In the “standard” group, 10⁶ TCID₅₀ MVA-C was given at weeks 16 and 20 in 1.0 ml was given at the same time as 100 µg CN54gp140 mixed with 5 µg GLA-AD at weeks 16 and 20 in 0.4 ml IM as above (with MVA-C into left and CN54gp140/GLA-AD into the right arms as shown, see **Table 1**).

**Humoral Assays**

**CN54gp140-Specific Antibody ELISA**

Serum and mucosal binding antibodies against recombinant CN54gp140 were measured using a standardized ELISA with minor modifications. 96-well ELISA plates were coated with 50 µl per well of capture antigen CN54gp140 (1 µg/ml) (Polymun, Austria). Human standards (IgG or IgA) were captured by coating wells with a combination of α-Human κ and α-Human λ (1:1 ratio) capture antibodies. After incubation at 37°C for 1 h, plates were washed with PBST then blocked for 1 h at 37°C with 200 µl/well of assay buffer (PBS + 1% BSA) then washed, as above (26). Standards were prepared by adding the required concentration of either human IgG or IgA. Serum samples were screened at 1:100 dilution, Softcup cervical mucosal samples at 1:10 dilution. Samples, standards, and controls (normal human sera) were added to triplicate wells. Detection antibodies were added following incubation and washing, either goat α-Human IgG-HRP or goat α-Human IgA-HRP detection antibodies. After incubation and washing, plates were developed by the addition of TMB substrate (KPL) followed by addition of 50 µl of Stop Solution (KPL). Absorencies were read immediately at 450 nm using a VersaMax plate-reader ( Molecular Devices). A response detected for both IgG and IgA was defined as OD A450 nm value >0.2; samples below this value were deemed negative or response not detected. Samples were further diluted following screening assays if positive with a series of dilutions in order to extrapolate a concentration expressed as microgram per milliliter of specific IgG or IgA using the ELISA software SoftMax Pro v 5.4. Serum samples that were positive by the

**TABLE 1 | Schedule of doses, formulation, and routes of immunization.**

| Group | Route of immunization; dose of vaccine | Weeks 0, 4, 8 | Weeks 16, 20 | Weeks 24, 28 |
|-------|---------------------------------------|---------------|-------------|-------------|
| 1 (n=20) | 4 mg DNA (CN54) in 1 ml (right arm) | 1 x 10⁶ TCID₅₀ MVA-C in 0.5 ml (left arm) + [100 µg CN54gp140 + 5 µg glucopyranosyl lipid adjuvant – aqueous formulation (GLA-AF)] | Nothing | |
| 2 (n=20) | 4 mg DNA (ZM96) in 1 ml (left arm) Intramuscular (IM) | 1 x 10⁷ TCID₅₀ MVA-C in 0.5 ml (left arm) | (100 µg CN54gp140 + 5 µg GLA-AF) in 0.4 ml (right arm) | |
neutralizing antibody responses against a panel of Tier 1 (MW965.26, MN.3, 00836-2.5, ZM197M-PB7) and Tier 2 (C1716_A3, Ce703010217_B6, HIV-2510-2) pseudo viruses were measured using TZM-bl cells in the lab of David Montefiori as described previously (27, 39). Briefly, pseudoviruses (TZM-bl assay) were incubated with serial dilutions of sera and added to their respective target cells. Luciferase expression was measured after 2 days (TZM-bl), and IC50s were determined as the serum concentration that reduced the background-subtracted relative light units by 50% compared to virus-only control wells.

Neutralizing Antibody Responses
Neutralizing antibody responses against a panel of Tier 1 (MW965.26, MN.3, 00836-2.5, ZM197M-PB7) and Tier 2 (C1716_A3, Ce703010217_B6, HIV-2510-2) pseudo viruses were measured using TZM-bl cells in the lab of David Montefiori as described previously (27, 39). Briefly, pseudoviruses (TZM-bl assay) were incubated with serial dilutions of sera and added to their respective target cells. Luciferase expression was measured after 2 days (TZM-bl), and IC50s were determined as the serum concentration that reduced the background-subtracted relative light units by 50% compared to virus-only control wells.

Cellular Assays

IFNy ELISPOT
Cellular immunogenicity was assessed by standardized IFNy ELISPOT assay using frozen PBMCs as previously described (32, 39). One day prior to assay setup, PBMCs were thawed in and rested overnight in RPMI medium containing 20% heat-inactivated fetal calf serum (HIIFC), glutamine, penicillin, and streptomycin (R20) (all supplied by Sigma, Poole, UK) at 37°C, 5% CO2. 96-well PVDF membrane (MSIPS4510 Millipore, UK) plates were coated with mouse anti-human IFNy (10µg/ml; MabTech clone 1-D1K) in sterile PBS. On the day of assay setup, coated ELISPOT plates were washed with sterile PBS and blocked with RPMI 10% HIIFCs (R10) for at least 1 h. Synthetic peptides (15-mers overlapping by 11aa; HPLC, purified >90%, JPT Germany) covering the HIV-1 gene inserts and CMV pp65 gene were dissolved and pooled in dimethyl sulfoxide (DMSO, Sigma), further diluted in PBS and R10 to achieve a final assay concentration of 1.5 µg/ml per peptide and 0.45% v/v DMSO. 100 µl volumes of HIV-1 peptide pools were added to ELISPOT plate wells in quadruplicate. The CMV pp65 peptide pool and phytohemagglutinin (PHA, 10 µg/ml) were plated as positive controls in duplicate wells for each. A negative control, quadruplicate wells containing a mock stimulus (0.45% v/v DMSO final concentration in R10) were used. Restered PBMCs were recovered and washed in R10 and viable cells counted using a Beckman Coulter Vi-Cell counter. A total of 200,000 viable PBMCs (in 50 µl) were added to all wells except for 1 well with R10 only (reagent control well). Plates were incubated at 37°C, 5% CO2 overnight (16–24 h). All subsequent steps were performed at room temperature. Plates were washed six times with PBS/0.05% v/v Tween 20 (Sigma) and the production of IFNy by T-cells was assessed by addition of 1 µg/ml biotinylated mouse anti-human IFNy antibody (clone 7-B6-1, Mabtech, Sweden) for 2–4 h. Plates were washed as before and ABC peroxidase–avidin–biotin complex (PK6100, Vector labs, UK) was added for 1 h, followed by three washes with PBS/Tween and three washes with PBS. Spots were developed with addition of filtered AEC/H2O2 substrate solution (Sigma) for 4 min. The reaction was stopped by washing plates under running tap water, plate underdrains removed, and plates allowed to dry overnight in the dark before spots in each well were counted using an automated AID ELISPOT reader (AutoImmun Diagnostika, Germany).

A positive response was defined by the following criteria: (1) average number of background-subtracted spots in a single pool >specified cutoff of 38 SFC/106 PBMCs (40). The cutoffs were derived from assessing peptide pool responses in PBMCs from 178 HIV-1 seronegative individuals; (2) for each pool, if the number of replicates was 2 or ≥3, then the coefficient of variation (standard deviation/mean) between replicates had to be ≤50% or ≤70%, respectively; (3) mean count had to be >4 times mean background; (4) mean background had to be ≤55 SFC/106 PBMCs. Samples with mean background >55 SFC/106 PBMCs were considered failures, were repeated, and excluded from all analyses if failed a second time. The breadth of responses was described in terms of the number of individual peptide pools to which each individual responded.

Flow Cytometry
Antigen-specific cytokine secretion was assessed using a validated seven-color polychromatic flow cytometry panel assessed at the IAVI human immunology lab in London. Previously frozen PBMCs were coinoculated with peptide pools matched to the inserts at 1.5 µg/ml (as previously described), 1 µg/ml SEB (Sigma-Aldrich, St. Louis, MO, USA), or mock stimuli and Brefeldin A (Sigma-Aldrich, Poole Dorset, UK) for 6 h at 37°C. Cells were stained for viability with LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Invitrogen, Eugene, OR, USA), fixed and then stained intracellularly using anti-CD-4 PeCF594 (clone RPA-T4), anti-CD8 BV421 (RPA-T8), anti-CD3 APC-H7 (SK7), anti-IFNy APC (B27), anti-IL2-PE (MQ1-17H12), and anti-TNFα-FITC (Mab11) (all Becton Dickinson, San Jose, CA, USA). Cells were washed and acquired on the same day. At least 5,000 CD8 and CD4+ CD3+ viable, singlet lymphocyte events were acquired using BD Fortessa II instruments. Data were analyzed and presented using FlowJo (version 9.8 Treestar, Ashland, OR, USA). Samples were failed where fewer than 5,000 events in the pre-defined populations were acquired or where mock IFNy responses were above 0.2% of either parental population. Flow cytometric analysis was performed at baseline, and 16 and 24 weeks for group 1, and additionally at 32 weeks for group 2.

Peptide Array Mapping
The microarrays were processed according to the manufacturers instructions with minor modifications (www.jpt.com). Briefly, the slides were pre-incubated with T20 blocking buffer (Thermo Fisher) for 10 min. Plasma samples were then added at a dilution of 1:100 in T20 blocking buffer and incubated for 2 h at room temperature with gentle shaking before washing five times with 2.5 ml TBS-Tween (0.5% Tween). The secondary mouse anti-human-IgG DyLight649 (JPT) was then incubated at room temperature for 1 h at a dilution of 1:5,000 in T20 blocking buffer. After five washings with 2.5 ml TBS-Tween, and five washes with double distilled de-ionized water, the slides were left to dry under a laminar flow hood. Samples from all timepoints from one individual were processed simultaneously. Slides were scanned on a GenePix 4000A scanner and processed using GenepixPro 6.0 software at 650 and 532 nm to generate a Tiff image file. The array layout was then added using the .gal file JPT_2758_V04.gal provided by JPT. Accuracy of the array alignment was controlled
and individual features were adjusted or excluded manually when needed. After this QA/QC step, .gpr files were generated and processed further into .dat files using R-program and the R-script “MakeDat_V05r_stat.R” to generate one fluorescent intensity (FI) value for the peptide-specific IgG response from the triplicates. Individual IgG responses were mapped using the R-script “MapAlign_BG_V11.R” after subtraction of FI values from baseline plasma. The array included the immunogen sequence CN54gp140 and nine other sequences from acute phase primary HIV isolates of subtypes A, C, B, CRF01_AE, and CRF02_AG to maximize coverage of global HIV diversity (Ahmed et al., in preparation).

### Statistical Analyses

All clinical and routine laboratory data were included in the safety analyses. Data sets included (i) modified intention to treat; all participants who were randomized and received at least one vaccination and (ii) per protocol (PP), all participants who completed vaccinations with no major protocol deviations. The primary safety outcome was expressed as a proportion of participants with 95% confidence interval, and groups were compared using Fisher’s exact test. The primary immunological outcome was the magnitude of serum CN54gp140-specific IgG 4 weeks after the final vaccination and we assumed a 100% response rate in the standard (reference) arm. The sample size was calculated on the basis of the binding antibody responses distributions described in the RV144 trial. In this trial, the reciprocal GMT of binding antibodies to subtype E gp120 was ~1:15,000 (log10: 4.18) and for subtype B gp120 was ~1:30,000 (log10:4.5). On the basis of previous trials, we assumed that everyone would respond to the CN54gp140 and that the titer of subtype C-specific binding antibody responses would be in the same range and at least 1:15,000 in the standard group and that a four-fold increase in the magnitude of would be immunologically relevant. This translates to an absolute difference of 0.6 on the log10 scale. In the absence of raw data from the Rv144 trial, we have assumed a standard deviation of 0.58 on the log 10 scale. In the absence of raw data from the RV144 trial, we have assumed a standard deviation of 0.58 on the log 10 scale.

### RESULTS

#### Participant Accrual, Study Population, and Compliance with Schedule

Of 75 healthy, low-risk, HIV-negative volunteers screened between 19th June 2013 and 10th January 2014, 40 were enrolled; the reasons for the 35 who were screened out are summarized in Figure 1. Twenty participants were enrolled at each center, and baseline characteristics are summarized in Table 2. The majority were white, half were female and the median age was 32 years (IQR 23–39). All randomized participants received the first immunization but two in the standard group did not complete the immunization schedule due to adverse events. In addition, two participants from the standard group missed the final visit at weeks 40 and 1 also missed the primary immunogenicity endpoint visit at week 32 (Figure 1).

### Table 2 | Baseline characteristics and median follow-up by treatment group.

|                  | Accelerated n = 20 | Standard n = 20 | Total n = 40 |
|------------------|--------------------|----------------|-------------|
| Number           | 20                 | 20             | 40          |
| Age (SD)         | 31 (25–38)         | 32 (22–39)     | 32 (23–39)  |
| Center           |                    |                |             |
| Imperial College | 10 (50%)           | 10 (50%)       | 20 (50%)    |
| Surrey           | 10 (50%)           | 10 (50%)       | 20 (50%)    |
| Gender           |                    |                |             |
| Female           | 10 (50%)           | 9 (45%)        | 19 (47.5%)  |
| Male             | 10 (50%)           | 11 (55%)       | 21 (52.5%)  |
| Ethnicity        |                    |                |             |
| Asian            | 2 (10%)            | 0 (0%)         | 2 (5%)      |
| Mixed            | 0 (0%)             | 2 (10%)        | 2 (5%)      |
| White            | 18 (90%)           | 18 (90%)       | 36 (90%)    |
| Weight (kg)      | 73 (63–82)         | 72 (67–78)     | 72.8 (66–78) |

### Routine laboratory parameters

|                              | Accelerated | Standard | Total |
|------------------------------|-------------|----------|-------|
| Hemoglobin (g/dl)            | 14 (13–15)  | 14 (13–14)| 14 (13–15)|
| White cell count (10⁹/l)     | 7 (5.3–8.2) | 6.4 (5.8–8.3) | 6.5 (5.6–8.2) |
| Neutrophils (10⁹/l)          | 4.1 (2.9–5.1) | 3.6 (3.3–5.1) | 3.8 (3.0–5.1) |
| Platelets (10⁹/l)            | 250 (236–288) | 259 (225–289) | 250 (219–288) |
| Lymphocytes (10⁹/l)          | 1.9 (1.6–2.3) | 1.9 (1.6–2.3) | 1.9 (1.5–2.3) |
| ALT (U/l)                    | 20 (19–25)   | 19 (14–27)  | 21 (16–27) |
| AST (U/l)                    | 21 (18–26)   | 23 (18–27)  | 23 (18–27) |
| Bilirubin (µmol/l)           | 10 (9–14)    | 11 (7–15)   | 10 (7–14)  |
| Creatinine (µmol/l)          | 71 (58–78)   | 71 (59–84)  | 71 (60–80) |
| Glucose (mmol/l)             | 4.7 (4.4–5.0) | 4.6 (4.5–4.9) | 4.6 (4.4–4.9) |

### DNA/ANA antibodies

|                | Accelerated | Standard | Total |
|----------------|-------------|----------|-------|
| Positive       | 4* (20)     | 0        | 4     |
| Negative       | 16 (80)     | 20       | 36    |

Follow-up (weeks, range) 43 (40–46) 45 (30–50) 44 (30–50)

*Positive only at a dilution of 1:160 which was deemed eligible.
Primary Safety Endpoints
Four (20%; 95% CI 5.73–43.66) participants in the standard group and one (5%; 95% CI 0.13–24.87) participant in the accelerated group experienced a primary safety endpoint, \( p = 0.342 \) (two-tailed Fisher’s exact test). Two of these were grade 3 laboratory adverse events that resulted in discontinuation of vaccinations. Both occurred in males aged 20 years in the standard group. The first occurred after the first DNA; the 7-day blood test revealed asymptomatic transaminitis (AST 375; Grade 3, ALT 109; Grade 2), which was confirmed 6 days later. Other blood tests, a viral screen, and ultrasound scan were normal. Apart from an episode of tonsillitis between screening and enrollment, treated with penicillin V, there were no other risk factors. The levels spontaneously returned to normal during the following week, but due to the temporal nature, a relationship could not be excluded and so vaccinations were discontinued. The second case occurred after administration of the second MVA-C. In between the immunization visit and the safety review, the participant reported an episode of vomiting after drinking around 12–14 units of alcohol, and strenuous exercise. The 7-day blood test revealed a transaminitis (AST 530; Grade 4, ALT 184; Grade 2). He was not able to return for 28 days at which time both were within the normal range. investigations including an ultrasound scan and blood tests for causes of viral and non-viral hepatitides were normal. Although it was felt that the more likely cause of the transaminitis was a combination of unusually high alcohol intake and strenuous exercise, there was a temporal relationship with vaccination and so vaccinations were discontinued. There were five others \( \geq \)grade 3 adverse events reported by three participants on diary cards during the 7 days after vaccination: severe malaise in a female accompanied by a headache 2 days after the first MVA-C/CN54gp140 GLA-AF, severe malaise in a male 5 days after the first CN54gp140 GLA-AF, and a severe/extreme lumpy swelling in a female 6 days after receipt of the first MVA-C and then again 3 and 6 days after the second MVA-C reported by the same participant.

There was one serious adverse event during the study; a female randomized to the accelerated group was referred to hospital by her GP with pain and suspected appendicitis 2 days after receiving her first combined MVA-C and CN54gp140 vaccination. She was treated with paracetamol for the pain (moderate grade according to the toxicity table) before being discharged after an overnight stay when the pain had resolved. The participant continued in the trial and received her last immunization without a repeat of this problem.

Other Adverse Events
All of the remaining solicited local, systemic and other events were mild or moderate. There were 10 laboratory abnormalities other than those reported above, all of these were mild (5 raised ALT, 3 AST, 1 hyperglycaemia, and 1 bilirubin). There were differences in reporting between the centers (125 by Surrey; 50 by Imperial) and by gender (119 by females; 56 by males).

Immunogenicity
All analyses presented below are derived from the PP data set and include 20 from the accelerated group and 17 from the standard group unless otherwise stated (1 participant from the standard group who received all vaccinations did not attend the primary immunogenicity visit and 2 did not receive all vaccinations).

Primary Immunogenicity Endpoint

CN54gp140-Specific Binding Antibody
At the primary endpoint 4 weeks after the final vaccination, all individuals who completed the schedule made CN54gp140-specific IgG. The GM titer and concentration of specific binding antibody in the accelerated group at the primary endpoint were 6,424 (95% CI 4,391–9,396) and 10.46 µg/ml (95% CI 7.3–15.0) and in the standard group 6,578 (95% CI 3,927–11,020) and 12.76 µg/ml (95% CI 8.7.0–18.75), respectively. There was no significant difference between the groups; as assessed by the ratio of the GM titer (0.98, 95 CI 0.53–1.79, \( p = 0.93 \)) or concentration (1.46, 95% CI 0.49–4.34, \( p = 0.49 \)). The response was first detected in both groups 4 weeks after the first MVA-C (week 20) when 15/20 (75%) in the accelerated and 8/18 (44.4%) in the standard group were positive—with a greater response in the accelerated group, \( p = 0.02 \). In both groups, the response increased significantly after each subsequent vaccination (Figure 2). In the accelerated group, the GMT at week 20 was 517, and this increased to 6,424 at week 24. In the standard group, the GM titer was 17 at week 20, increasing to 246 at week 24, 3,596 at week 28, and 6,578 at week 32. In both groups, the response fell away again by week 40; to GMT 1,302 and 2,536 in the accelerated and standard groups, respectively, a difference which was significant (\( p = 0.02 \)) (Figure 2). There was no CN54gp140-specific serum IgA detected at any time point.

Mucosal Antibody Responses
Of the mucosal sites sampled, CN54gp140-specific IgG was only detected in cervicovaginal secretions, with no specific responses detected in either urethral or rectal samples (Figure 3). The only samples included in the analyses of mucosal secretions were collected from women using Instead cups. There was no CN54gp140-specific IgG detected in samples at baseline, and at the primary endpoint there was no difference in the frequency of responders between the groups; 70% (7/10) women had detectable CN54gp140-specific IgG in the accelerated group as compared to 88% (7/8) in the standard group (\( p = 0.59 \), Fisher’s exact test). The GM concentration of cervicovaginal CN54gp140-specific IgG was 0.11 µg/ml (95% CI 0.01–1.28) in the accelerated group compared with 0.43 µg/ml (95% CI 0.05–3.7) in the standard group 4 weeks after the final vaccination. There was no CN54gp140-specific IgA detected in cervicovaginal samples.

Neutralizing Antibody Responses
Neutralizing antibody responses were detected against two Tier 1A Env-pseudoviruses (Figure 4). At the primary endpoint 9/20 (45%) participants in the accelerated group showed neutralization of subtype C MW965.26 virus (closest match to CN54gp140) compared to 14/17 (82%) in the standard group, a difference which was statistically significant (\( p = 0.04 \), Fisher’s exact test) with higher median titer neutralization in the responders from the standard relative to the accelerated group (median titer of 51 and 78, respectively). There was also a trend toward a higher
frequency response to MN.3 (Tier 1 subtype B) in the standard group (10 versus 35% positive, $p = 0.107$). There was no neutralization detected against two Tier 1B Clade C viruses (00836-2.5, ZM197M-PB7) or against two Tier 2 clade C viruses (Ce1176_A3, Ce703010217_B6, HIV-25710-2.43).

**Peptide Array Mapping of the Env-specific Antibody Response**

Vaccine-induced Env-specific IgG responses to linear 15-mer peptides (Table 3) were mapped using a custom designed peptide micro array approach in subjects of accelerated group ($n = 12$) and standard group ($n = 11$) 4 weeks after the final vaccination. The immunodominant regions (IDRs) targeted and magnitude of region-specific responses were largely similar between the two groups (Figure 5). IDRs were exclusively located within gp120 with little recognition of gp41. Basic characteristics of IDR-specific IgG responses including the representative peptide sequence targeted and mean fluorescence intensity within each group are summarized in Figure 5. Within gp120, four consecutive peptides covering the tip of the V3 region (indicated as peak 5, aa300 to 320 (HxB2 reference strain) were targeted by >90% of vaccinees with a high mean fluorescence intensity (MFI) (referring to the highest measured response, if multiple peptides covered for this region) of above 50,000 units in both groups. Other IDRs were located in the C1 region (peak 1; HxB2 aa position 104–124 and peak 2; HxB aa117–136) with maximum MFIs of 43,000 and 25,000 in standard and accelerated groups, respectively; in the
TABLE 3 | Antigenic peaks of recognition in Env.

| Peak number | HXB2 | Env region | Representative sequence | MFI standard | MFI accelerated |
|-------------|------|------------|--------------------------|--------------|----------------|
| 1           | 104  | C1a        | MHEDIISLWDQSLKPV         | 34650        | 19507          |
| 1           | 107  | C1a        | DVISLWDQSLKPCVK          | 43478        | 25183          |
| 1           | 109  | C1a        | ISLWDQSLKPCVKLT          | 41274        | 21634          |
| 2           | 119  | C1b/V1     | SVKLTPSVTLNSTD           | 11993        | x              |
| 2           | 121  | C1b/V1     | KLTLPCVTLNCTNAK          | 29195        | x              |
| 3           | 200  | C2         | ATOACPKVTTFDP         | 30593        | 25445          |
| 4           | 245  | C2         | VOCVQIKPVSTQL          | 33780        | 36173          |
| 4           | 249  | C2         | HGIKPVSTQLLLNG          | 15699        | 20843          |
| 5           | 300  | V3         | GNNTKRSIRIGPQQT         | 44475        | 40678          |
| 5           | 301  | V3         | NNTRKSIHIGPQAF          | 60570        | 59711          |
| 5           | 304  | V3         | RKSNIGPGGRAFYAT         | 59915        | 59186          |
| 5           | 305  | V3         | TSIRGPQRTYATG          | 59689        | 56526          |
| 6           | 429  | C4         | EVGKAMAYAPPiKQI         | x            | 15762          |
| 6           | 433  | C4         | AMYAPPiKQiKCL5          | x            | 19922          |
| 7           | 475  | C5         | GDMRNWRSELKYKK          | 34577        | 22160          |
| 7           | 475  | C5         | MKDNRWSELGYKVV         | 37522        | 22782          |
| 8           | 491  | C5         | IKPLGAPTTTTKRR          | 35026        | 35758          |

Summary of HxB location, Envelope region, representative peptide sequences, and mean fluorescence intensity (MFI) of the most frequently recognized antigenic regions in Env displayed in Figure 5 and the MFI of each peak from standard (n = 11) and accelerated (n = 12) groups.

FIGURE 5 | Specificity of systemic binding antibody responses to Env by group. Frequency of recognition of linear overlapping peptides spanning the HIV envelope in plasma samples from the accelerated (n = 12, upper panel) and the standard groups (n = 11, lower panel). The y axis shows the proportion of individuals recognizing the specified peptides and the x axis denotes the distribution of linear peptides along the envelope with relevant regions of interest highlighted.

C2 region (peak 3; HxB_aa200–215 and peak 4; HxB_aa245–264) with MFIs between 25,000 and 35,000; and in the C4 (peak 6 HxB2_aa429–457) and C5 regions (peak 7, HxB2_aa473–490 and peak 8, HxB2_aa491–504) were targeted with MFIs between 20,000 and 38,000. All these IDRs were recognized by 70% of vaccines in at least one group. There was no significant differences between the groups in terms of the number of epitopes recognized, the magnitude of individual responses or the sum of fluorescence intensity values for all peptide variants recognized that were included in the array (p = 0.21).
T-Cell ELISpot Responses

There were no IFNγ ELISpot responses at baseline and 8 weeks after the third DNA vaccination (week 16) responses were seen in a minority of individuals to Env peptide pools (20.5% overall). At the primary endpoint, there was no difference in either the frequency or magnitude of ELISpot responses between groups; 85 and 82.4% responded to any pool in the accelerated and standard groups, respectively, at the primary endpoint ($p = 1.00$) with overall GM values of 111 and 147 SFC/10⁶ PBMCs ($p = 0.44$).

**Figure 6.** All responding individuals recognized one or both Env peptide pools (75.0 and 76.5% recognizing Env pool 1 and 65.0 and 64.7% recognizing Env pool 2 for the accelerated and standard groups, respectively, $p$ values $>0.99$) and the magnitude of these responses was similar between groups [medians 70–189 SFC/10⁶ PBMCs for the two Env pools ($p = 0.09–0.32$)]. Gag peptide-specific responses were relatively modest and detected in only 25% of the accelerated and 23.5% of the standard group ($p = 1.00$) with similar magnitude (median 58 and 86 SFC/10⁶ PBMCs, $p = 0.28$). There were no responses to the 5’ Pol pool in either group and none of the accelerated group and 17.6% of the standard group responded to the 3’ Pol pool ($p = 0.09$, median 43 SFC/10⁶ PBMCs). None of the accelerated group and 5.9% of standard group responded to Nef peptides ($p = 0.46$, 1 response of 179 SFC/10⁶ PBMCs in the standard group). At this time point, the mean number of peptide pools recognized (out of a total possible of 6) for each subject was similar between groups; 1.65 and 1.88 for the accelerated and standard groups respectively (median of 2 for both groups, $p = 0.63$). In terms of magnitude, responses to Env pools peaked 4 weeks after the second MVA-C/ CN54gp140 (median 111 SFC/10⁶ PBMCs) in the accelerated group and 4 weeks after the first MVA-C in the standard group (median 213 SFC/10⁶ PBMCs). While the great majority of responses in both groups recognized Env or Env plus Gag peptides, recognition of ENV in combination with Nef or 3’Pol or of Gag peptides was only seen in the standard group—accounting for approximately 17% of all responses (data not shown).
accelerated group, responses to Env and Gag peptides dropped between weeks 24 and 40 ($p = 0.04, 0.02$) whereas in the standard group there was no significant change ($p = 0.4, 0.65$). At week 40, the responses to Env and Gag peptide pools was of greater magnitude in the standard than the accelerated group ($p = 0.03, 0.02, 0.091$, respectively) and more frequent to Env peptides, with $71\%$ responding to both Env peptide pools in the former compared to $37$ and $47\%$ in the latter ($p = 0.09$ for responses to Env 1 pool) and this was also true of responses to Gag peptide pools with $30\%$ responding in the standard and $5\%$ in the accelerated group.

### Intracellular Cytokine Responses

Overall, intracellular cytokine responses were modest and results are therefore descriptive. The majority of responses were polyfunctional and focused toward Env rather than Gag peptide pools. Response rates to any antigen at any post-baseline visit, for both CD4 and CD8 populations, were higher in the standard than the accelerated group, $50$ versus $30\%$ respectively for CD4+, and $33.3$ versus $10\%$ for CD8+ lymphocytes, but these differences were not statistically significant (data not shown). CD4 and CD8 responses to all antigens were predominantly polyfunctional, with IFNγ being the dominant cytokine (Figure 7). The standard group tended toward higher CD4 responses (IFNγ+TNFα+) while both groups had comparable CD4 responses (the majority being IL2+IFNγ+). In the standard group, responses seemed to peak at week 24 and wane at week 32 in CD4 lymphocytes but were more persistent in some CD8 lymphocytes (data not shown).

### DISCUSSION

We have compared two vaccination regimens using identical DNA-C, MVA-C, and GLA adjuvanted CN54gp140 with the aim of assessing the safety and immunogenicity of a shortened regimen in which the MVA and adjuvanted protein were combined. We expected strong Env-specific CD4+ T-cells after DNA and MVA and Env-specific binding antibodies in everyone after adjuvanted gp140 and the study was powered to detect a four-fold difference in the magnitude of this response between groups. As expected, $100\%$ individuals made strong CN54gp140-specific antibody irrespective of regimen, but combining the vaccines had no detectable impact on the magnitude or specificity of the antibody response as assessed by the recognition of linear peptides. This pattern was characterized by strong recognition of V3 with notably little recognition within gp41—in spite of its presence in the DNA and gp140 vaccines. The immunogens also induced recognition of linear epitopes within C2 and C4, but their significance, if any, is unknown. Despite these binding

---

**FIGURE 7** | Heatmaps showing the frequency of different cytokine responses by T-cell subset over time by group. Overall frequency of different combinations of three cytokines (IFNγ, IL2, and TNFα) produced by CD4 (A) and CD8 (B) T-cells responses to combinations of P5/6 Env peptide pools by week. The highest frequency (% of total) is shown in red and the lowest in blue (scale depends on maximal response). Due to the low frequency of responses, no formal statistical comparisons were made between the groups.
antibody responses, neutralizing antibody responses were disappointing and only seen to Tier 1A pseudoviruses, similar to our previous experiences using this adjuvanted protein (27, 28). Interestingly, however, the frequency and titer of the responses was inferior when vaccines were combined to two Tier 1A pseudoviruses. There was no difference in the overall frequency or specificity of T-cell ELISpot responses which were seen in >80% individuals irrespective of group and tended to be CD4+ and specific for Env peptide pools. While the great majority of IFNγ ELISpot responses were seen to Env peptide pools in both groups, recognition of Gag, Nef and Pol peptides was less frequent in the accelerated group suggesting that combining the vaccines might have led to further polarization of immune responses. Cytokine responses were relatively modest, but also less frequent or less polyfunctional in both CD4+ and CD8+ compartments when the MVA and CN54gp140 were combined. There was no significant impact of combining the vaccines upon tolerability. Although two participants experienced events that resulted in discontinuation of immunizations, these followed different immunogens (DNA-C, MVA-C) and there were alternative explanations for the asymptomatic elevation in transaminases in each case. The great majority of adverse events were mild in line with our previous experience using the same adjuvanted protein in different settings (27, 28).

Even though we controlled for variables such as site and gender, the study has limitations; overall statistical power was compromised by the fact that we did not have 40 in the final analyses as planned. Nevertheless, there was clear evidence that combining MVA and gp140 led to attenuation of certain T-cell and B-cell immune responses. Both regimens were shorter overall than used in previous studies using similar homologous (22–24) or heterologous DNA and MVA (26, 42) and it remains possible that the time between DNA prime and MVA boost (8 weeks) might have been too short to allow for the optimal maturation of immune responses. The use of a common and semi-quantitative assay for the measurement of CN54gp140-specific IgG antibody allows for direct comparison across our different trials. The median CN54gp140-specific binding antibody response seen here (12.8 µg/ml) exceeds that seen in the Mucovac 2 trial (UK HVC_001) after three doses of CN54gp140/GLA-AF IM in the absence of DNA priming (4.2 µg/ml) (27), but is lower than seen in the TaMoVac 01 trial (UK HVC_00 2) after boosting twice with GLA-AF adjuvanted CN54gp140 30–71 weeks after priming with DNA and MVA (17.8 µg/ml) (28). This supports the value of DNA/MVA priming and suggests that the long gap between prime and boost could be important. Sallusto and colleagues propose a minimum gap of 12 weeks and note that if boosting is too frequent, responding cells might be preferentially driven to terminal differentiation resulting in attenuation of immunity (43).

Our decision to use immunogens expressing matched subtype C inserts was driven by our commitment to a vaccine for use in Sub-Saharan Africa as well a belief that this approach would elicit high titer binding antibodies and so favor functional/neutralizing antibodies. In addition to the logistical advantages offered by fewer vaccinations, we were interested in combining the pox and protein in light of the results of the RV144 trial which included combined canarypox and alum adjuvanted gp120 and was the first ever trial of an HIV vaccine to show (modest) efficacy. In UK HVC_003 overall, immunogenicity was somewhat disappointing and it remains possible that the combined MVA and adjuvanted gp140 protein may have overwhelmed the pool of antigen-specific/innate immune cells, as offered as one explanation of the attenuation in responses sometimes seen when certain pediatric vaccines are combined (44, 45) and which might be particularly associated with MVA at it has been shown to be highly immunogenic and to preferentially deplete antigen presenting cells (46–48). Immunogenicity may have been further compromised in the accelerated group as a result antigenic competition (even though the vaccines were administered into opposite arms) as has been suggested to occur in response to response to certain combinations of conjugated vaccines (49) and observed more recently in an HIV vaccine trial in South Africa (25). The choice of adjuvant was partly practical as we had access to GLA-AF through the UK HVC and had already used it with the same gp140 protein (27, 28). In our hands, the GLA-AF (MLPA) adjuvant has previously been shown to be potent for antibodies at equivalent (3 × 100 µg) and lower (3 × 20 µg) doses (27) (in the absence of DNA/MVA), and we had every reason to suspect that priming would further enhance these responses. We expected the immunogens to be at least as immunogenic as those used in RV144 in both groups and, based on our previous experiences with DNA and MVA, predicted that they would be more potent for T-cells.

In light of these findings, we remain cautious about the accelerated regimen, and feel that the combined MVA-C and adjuvanted GLA-AF warrants further evaluation in a regimen with a longer gap between priming and boost. We believe this trial provides further support for exploring the clinical efficacy of a priming regimen including DNA, with at least 12 weeks prior to boosting. The precise contribution of adjuvanted protein (if any) is yet to be defined. While Churchyard and colleagues reported no clear benefit of DNA priming on Env-specific antibody responses, T-cell responses appeared augmented by the priming although overall immunogenicity in the trial was lower than seen previously using the same vaccines in a different population (25). In light of our previous experience with a variety of immunogens, we remain committed to the inclusion of DNA as we believe balanced immune responses highly desirable. We await data from a direct comparison of the specificity of antibody responses from trials using different heterologous prime boost regimens (including RV144 and Tamovac 01) with this one to inform our selection of immunogens to take forward. Non-neutralizing IgG antibody responses targeting V2 have been shown to correlate with a reduced risk of HIV using a variety of different approaches, although we did not see much response to linear peptides within this region (9, 50, 51) suggesting perhaps that they are associated with the subtype E gp120 protein. We did however see strong recognition of the V3 loop in both groups and this has been described as characteristic of the responses seen during natural infection (27) and also in other vaccine trials including RV144-when the response correlated with reduced risk of HIV acquisition in a subset of individuals.
(51). In conclusion, the vaccines were potent irrespective of regimen, but immunogenicity was lower than anticipated, and we cannot exclude the possibility that this was due to the relatively short regimens. Our data suggest that combining MVA and CN54gp140/GLA-AF in this relatively short regimen had no significant impact on safety and also no impact on the magnitude of CN54gp140-specific systemic antibody responses and the strategy may have attenuated immunogenicity as reported previously (25).

AUTHOR CONTRIBUTIONS
SM, JW, RS, SJ, JG, DL, RW, and ME oversaw and/or designed the study/immunogens. KQ, AG, SM, AM, SJ, AC, RT, and DL were involved in the day to day running and conduct of the study. AC, PM, PH, JK, CG, YN, MA, and DM were involved in laboratory analyses, interpretation of results, and drafting figures. LD, SJ, and GB conducted the statistical analyses. SJ drafted the manuscript with editorial support and comment from PM, PH, SM, AC, RS, CG, JW, DM, RW, ME, LD, and GB.

ACKNOWLEDGMENTS
We would like to thank the volunteers who agreed to participate in the study and gave generously their time and the clinic teams at both centres. We would also like to thank Josephine Cox and Deborah King from IAVI and the Human Immunology Lab and Kate Skinner at Imperial College for their input. The neutralizing antibody responses were analysed as part of NIH HHSN272101100016C.

FUNDING
This study was funded through core funding from the Wellcome Trust via UKHVC (083844/Z/07/Z), MRC (G1001784), Imperial NIHR BRC, and NIH.

REFERENCES
1. Harmon TM, Fisher KA, McGlynn MG, Stover J, Warren MJ, Teng Y, et al. Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in low- and middle-income countries. PLoS One (2016) 11(1):e0146387. doi:10.1371/journal.pone.0146387
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kamarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 365(6):493–505. doi:10.1056/NEJMoai1105234
3. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191(5):654–65. doi:10.1086/428404
4. Pititsutthum P, Gilbert P, Gurwitz H, Weissman IL, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 194(12):1661–71. doi:10.1086/508748
5. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study); a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 372(9563):1881–93. doi:10.1016/S0140-6736(08)61591-3
6. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Pambuli study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 11(7):507–15. doi:10.1016/S1473-3099(11)70098-6
7. Hammer SM, Sobieszczyn ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 369(22):2083–92. doi:10.1056/NEJMoa1310566
8. Rkers-Ngarms S, Pititsutthum P, Nitsayaphan S, Kaeukwangwl J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361(23):2209–20. doi:10.1056/NEJMoab0908492
9. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomas Ar, SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366(14):1275–86. doi:10.1056/NEJMoab1113425
10. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, HWang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 86(21):11531–32. doi:10.1128/JVI.01023-12
11. Tomas Ar, GD, Ferrari G, Shen X, Alam SM, Liao HW, Pollara J, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 110(22):9019–24. doi:10.1073/pnas.1301456110
12. Chung AW, Ghebremary M, Robinson H, Brown E, Choi I, Lane S, et al. Polyclonal Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAXX03 vaccines. Sci Trans Med (2014) 6(228):228ra38. doi:10.1126/scitranslmed.3007776
13. Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 124(9):3879–90. doi:10.1172/JCI75539
14. Liao HP, Bonsignori M, Alam SM, Mcellan JS, Tomaras GD, Moody MA, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 38(1):176–86. doi:10.1016/j.immuni.2012.11.011
15. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, HWang KK, et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol (2014) 88(14):7715–26. doi:10.1128/JVI.01516-14
16. Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, et al. A multi-vector, multi-envelope HIV-1 vaccine. J Pediatr Pharmacol Ther (2007) 12(2):68–76. doi:10.1586/1551-6776.12.2.68
17. Amara RR, Smith JM, Stapprans SL, Montefoi DC, Villinger F, Altman JD, et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified Vaccinia virus Ankara vaccine. J Virol (2002) 76(12):6138–46. doi:10.1128/JVI.76.12.6138-6146.2002
18. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 21(3):346–51. doi:10.1016/j.coi.2009.05.016
19. Thorner AR, Lencack AA, Goudsmit J, Lynch DM, Ewald BA, Denholz M, et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol (2006) 80(24):12099–12. doi:10.1128/JVI.01749-06
20. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A (2012) 109(50):E3503–12. doi:10.1073/pnas.1208721109
21. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines (2008) 7(2):175–91. doi:10.1586/14760584.7.2.175
22. McCormack S, Stohr W, Barber T, Bart PA, Harari A, Moog C, et al. EVO2: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 26(25):3162–74. doi:10.1016/j.vaccine.2008.02.072
23. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjina-Rais E, et al. An HIV-1 clade C DNA vaccine, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 205(1):63–77. doi:10.1084/jem.20071331
24. Levy Y, Ellefsen K, Stoevel B, Bart PA, Lilleved J, Unany O, et al. Optimal Priming of Poxyvirus Vector-Based Regimens Requires 3 DNA Injections; Results of the Randomised Multicentre EV03/ANRS Vac20 Phase I/II Trial. 17th Conference on Retroviruses and Opportunistic Infections (78LB). San Francisco (2010).
25. Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, et al. Sequential immunization with gp140 boosts immune responses primed by modified vaccinia Ankara or DNA in HIV-infected South African participants. *PLoS One* (2016) 11(9):e0161753. doi:10.1371/journal.pone.0161753

26. Nilsson C, Hejdedem B, Godoy-Ramirez K, Tecleab T, Scarletti G, Brave A, et al. HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccines: a phase I randomized trial. *PLoS One* (2015) 10(6):e0131748. doi:10.1371/journal.pone.0131748

27. Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, et al. Comparative immunogenicity of HIV-1 gp140 vaccine delivered by parenteral, and mucosal routes in female volunteers; MUCOVAC-C2, a randomized two centre study. *PLoS One* (2016) 11(5):e0152038. doi:10.1371/journal.pone.0152038

28. Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, et al. Boosting with subtype C CN54gp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a phase I trial. *PLoS One* (2016) 11(5):e0155702. doi:10.1371/journal.pone.0155702

29. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al. DNA vaccines formulated as a DNA prime, NYVAC, and envelope protein boost. *J Virol* (2012) 79(14):8828–34. doi:10.1128/JVI.00264-12

30. Wise MC, Hutnick NA, Pollara J, Myles DJ, Williams C, Yang J, et al. An enhanced synthetic mucosal DNA vaccine candidate delivered vaginally. *Frontiers in Immunology* (2015) 7:409:131–46. doi:10.3389/fimmu.2015.00137

31. Buttery JP, Ridder B, Giorgi EA, Vandergraft N, Saunders KO, Balachandran H, et al. Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and envelope protein boost. *J Virol* (2015) 89(12):6462–80. doi:10.1128/JVI.00383-15

32. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenosvirus subtype 35 vector vaccine in healthy uninfected adults. *PLoS One* (2012) 7(8):e41936. doi:10.1371/journal.pone.0041936

33. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope A, et al. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. *PLoS One* (2011) 6(9):e25165. doi:10.1371/journal.pone.0025165

34. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Kostler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B) recombinant strain in China. *J Virol* (2000) 74(21):11367–76. doi:10.1128/JVI.74.21.11367-11376.2000

35. Palet M, Chang M, Stadlmann J, Altmann F. Glycan profiles of the 27 cell and enzyme-linked immunospot assays in laboratories from three continents. *Clin Vaccine Immunol* (2009) 16(2):147–55. doi:10.1128/CVI.00326-08

36. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. *Cytometry A* (2011) 79(2):167–74. doi:10.1002/cyto.a.21015

37. Minuseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase Ia randomized clinical trial. *PLoS One* (2015) 10(4):e0119629. doi:10.1371/journal.pone.0119629

38. Gallust E, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. *Immunity* (2010) 33(4):451–63. doi:10.1016/j.immuni.2010.10.008

39. Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). *Cochrane Database Syst Rev* (2009) 3:CD005530. doi:10.1002/14651858.CD005530.pub2

40. Guzman E, Cubillos-Zapata C, Cottingham MG, Gilbert SC, Prentice H, Charleston B, et al. Modified Vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. *J Virol* (2012) 86(10):5452–66. doi:10.1128/JVI.00264-12

41. Liu L, Chavan R, Feinberg MB. Dendritic cells are preferentially targeted among hematolymphocytes by modified Vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. *BMC Immunology* (2008) 9:15. doi:10.1186/1471-2474-9-15

42. Bocu-M, Riddell A, McCormack and Weber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.